PMC8384575_01
Timeline with main clinical events and patient's PSA variation from January 2016 to June 2020.
RRU-13-597-g0001.jpg
PMC8384575_01_RRU-13-597-g0001.jpg
f0001
The PSA doubling time was of 3.3 months (https://www.mskcc.org) (Figure 1).
[68Ga]Ga-PSMA-11 PET/CT and MRI findings in the patients showing heterogeneous mass in the right temporal region with central cystic components and peripheral solid components surrounded by peri-lesional edema finally diagnosed as intracranial metastasis due to prostate cancer. (A) [68Ga]Ga-PSMA-11 PET/CT MIP image from vertex to upper tight; (B) trans-axial PET/CT superimposed image showing increased radiopharmaceutical uptake at the right temporal lobe, further confirmed by MRI study; (C) trans-axial ADC map; (D(i), D(ii)) trans-axial contrast-enhanced T1-weighted images; (E(i), E(ii)) trans-axial T2-weighted images; (F(i), F(ii)) trans-axial FLAIR images; (G-J) At histopathological level, the tumor cells presented with rounded nuclei with small nucleoli, forming acinar structures (G), and expressed ERG (nuclear staining) (H), PAP (I) e PSA (J).
RRU-13-597-g0002.jpg
PMC8384575_02_RRU-13-597-g0002.jpg
f0002
Follow-up brain MRI excluded residual disease (Figure 2D(ii)-F(ii)).
PMC8384575_02
[68Ga]Ga-PSMA-11 PET/CT and MRI findings in the patients showing heterogeneous mass in the right temporal region with central cystic components and peripheral solid components surrounded by peri-lesional edema finally diagnosed as intracranial metastasis due to prostate cancer. (A) [68Ga]Ga-PSMA-11 PET/CT MIP image from vertex to upper tight; (B) trans-axial PET/CT superimposed image showing increased radiopharmaceutical uptake at the right temporal lobe, further confirmed by MRI study; (C) trans-axial ADC map; (D(i), D(ii)) trans-axial contrast-enhanced T1-weighted images; (E(i), E(ii)) trans-axial T2-weighted images; (F(i), F(ii)) trans-axial FLAIR images; (G-J) At histopathological level, the tumor cells presented with rounded nuclei with small nucleoli, forming acinar structures (G), and expressed ERG (nuclear staining) (H), PAP (I) e PSA (J).
RRU-13-597-g0002.jpg
PMC8384575_02_RRU-13-597-g0002.jpg
f0002
Follow-up brain MRI excluded residual disease (Figure 2D(ii)-F(ii)).